secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2023-08-02T23:59:59+00:00
Accession:  0001558370-23-012810
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas Q2 net loss $40.3M ($0.56/sh); cash $480M; EDIT-301 on track for 20 patients by year-end
--------------------------------------------------------------------------------

- Net loss $40.3M ($0.56 per share) vs. $53.5M ($0.78) in Q2 2022.
- Cash, cash equivalents and marketable securities $480.0M as of June 30, 2023.
- EDIT-301 RUBY trial (SCD) on track to dose 20 total patients; clinical update by year-end.
- EDIT-301 EDITHAL trial (TDT) commenced parallel dosing; update expected by year-end.
- Erick Lucera appointed CFO and Linda C. Burkly, Ph.D. appointed CSO.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/0001558370-23-012810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000155837023012810/edit-20230802x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-012810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer